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There are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or
children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment
on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that
Vitamin D treatment has potential antifibrotic properties in liver disease.
Trial Design
To date, however, there are no studies that have tested the combination of Docosahexanoic
acid (DHA) and vitamin D treatment which may benefit the whole spectrum of disease in
NAFLD. Our aim therefore, was to test the effect of daily DHA (500 mg) plus vitamin D (800 IU)
treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a random-
ized, double-blind placebo-controlled trial.
Methods
The 41/43 patients completed the study (18-treatment, 23-placebo). At 12 months: i) the
main outcome was liver histology improvement, defined by NAS; ii) the secondary outcome
was amelioration of metabolic parameters.
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Results
DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment
group (5.4 v1.92; p<0.001 for baseline versus end of study). There was no change in fibrosis
score, but a reduction of the activation of hepatic stellate cells (HSC) and fibrillar collagen
content was noted (3.51±1.66 v. 1.59±1.37; p = 0.003) in treatment group. Moreover, the tri-
glycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42)
were all decreased with treatment.
Conclusion
DHA plus vitamin D treatment improved insulin-resistance, lipid profile, ALT and NAS.
There was also decreased HSC activation and collagen content with treatment.
Introduction
Following the epidemic of obesity and metabolic syndrome recorded in children and adoles-
cents in the last couple of decades, nonalcoholic fatty liver disease (NAFLD) has become the
main cause of chronic liver disease in these groups. In Western countries, the prevalence of
NAFLD is 20–30% in the pediatric population and 70–80% in obese children [1]. NAFLD is
considered a “multi-hit” disorder, in which genetic, epigenetic and environmental factors
interact causing the onset and progression of liver damage [2]. Recent studies have demon-
strated that approximately 25% of children with NAFLD have NASH and interesting data
derived from longitudinal studies have indicated that hepatic fibrosis is the most important
prognostic marker of progression of liver disease [3,4]. The rate of progression of liver disease
in NAFLD is slow with an estimated average of 7 years elapsing between the development of
NASH with fibrosis in patients who had prior nonalcoholic fatty liver [5,6]. Because the pres-
ence of liver fibrosis predicts liver-related outcomes and mortality, blocking mechanisms of
fibrogenesis is a key therapeutic goal in the treatment for NASH [6]. Fibrosis is characterized
by an excessive deposition of extracellular matrix (ECM), with increases in total collagen con-
tent and in fibril-forming collagens (Type I, III and IV) [7]. These changes induce dysfunction
and activation of the hepatic stellate cells (HSCs) with development and progression of
fibrogenesis.
Lifestyle interventions, consisting of a weight decreasing diet and increases in physical exer-
cise, remain the cornerstone of treatment of pediatric NAFLD, even if several studies indicate
improvement only in metabolic parameters and liver steatosis [8,9]. Consequently, in the last
decade, several pharmacological approaches have been tested that are focused on ameliorating
mechanisms of liver damage. Unfortunately, none of the tested drugs to date has produced
unequivocal results with the most effective treatments showing limited efficacy and worrying
side effects in studies in adults. Omega-3 fatty acid treatment is potentially safe in adults and
children, and docosahexaenoic acid (DHA) treatment in children and omega-3 fatty acid treat-
ment producing > 2% DHA tissue enrichment in adults has shown promising results to
decrease liver fat in patients with NAFLD [10–12].
Recently, vitamin D deficiency (VDD) has been associated with obesity, metabolic syn-
drome and cardiovascular risk in adults and children [13]. VDD occurs frequently among
healthy children, with a rate of 55% in the American pediatric population [14]. Moreover, sev-
eral studies have reported that VDD is common in patients with NAFLD and importantly,
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VDD is associated with increased risk of steatosis, necroinflammation and fibrosis in both
adults and children with biopsy-proven NAFLD [15–18]. Several studies in humans and in
animal models indicate that VDD contributes to increased oxidative stress and systemic
inflammation [19]. Furthermore, emerging evidence suggests a role for VDD in fibrogenesis,
with the potential therefore for an anti-fibrotic effect of vitamin D treatment [20]. The avail-
able data to date suggests that vitamin D may reduce fibrotic processes inhibiting the expres-
sion of transforming growth factor beta (TGF-β) and suppressing the deposition of collagen
Iα1 and the activation of alpha-smooth muscle actine (α-SMA) positive HSCs [21].
Therefore, given the potential benefits of both DHA treatment and vitamin D treatment to
ameliorate the features of NAFLD/NASH, the aim of the present study was to undertake a
proof of concept, randomized double blind placebo-controlled trial (RCT) to test the potential
efficacy and tolerability of a mixture of DHA and Vitamin D in children and adolescents with
vitamin D deficiency and biopsy-proven NAFLD
Materials and Methods
Study population and design
An RCT was undertaken to examine the efficacy and safety of a mixture of vitamin D (800 IU)
and DHA (500 mg) orally once daily, versus identical placebo for 24 weeks on hepatic histol-
ogy and metabolic parameters in children and adolescents with biopsy-proven NAFLD. Sixty-
six white European patients (4–16 years) with liver biopsy-proven NAFLD, referred to the
Hepato-Metabolic Department of “Bambino Gesu`” Children’s Hospital (Rome, Italy) between
March 2014 and April 2015, were evaluated for the present study. Patients were recruited and
studied between March 2014 and April 2015.
Children were eligible for the study if they were between: 4 and 16 years of age, had a liver
biopsy result consistent with a diagnosis of NAFLD/NASH, and also had decreased serum vita-
min D levels (< 20 ng/ml), aminotransferases (ALT) levels <10 upper limit of normal (ULN),
and no laboratory and/or clinical signs of liver decompensation. Moreover, in all children
other causes of liver disease, such as viral liver disease, autoimmune hepatitis, Wilson’s disease,
α-1-antitrypsin deficiency, celiac disease, alcohol consumption (any quantity), use of drugs
known to induce fatty liver, were also excluded.
Patients were randomized to receive capsules combining 500 mg of docosahexaenoic acid
and 800 IU of Vitamin D (Treatment arm) or identical capsules as placebo (Placebo arm).
The dosage of the DHA and vitamin D intervention were determined based on the available
evidence in obese patients with NAFLD. As previously reported by our group, DHA supple-
mentation improves liver steatosis and insulin sensitivity in children with NAFLD with similar
effects for doses of 250 and 500 mg/day [22]. As for vitamin D, several expert groups, including
the American Academy of Pediatrics, have recently revised the recommended supplementa-
tion dosages. In this position paper, 600–1.000 UI/day of vitamin D have been recommended
in adolescents with risk factors for vitamin D deficiency, such as obese adolescents group [23].
Based on these finding, we treated our patients with 800 UI/day in the treatment arm.
A computer-generated randomization sequence assigned participants in a 1:1 ratio to treat-
ment with Vitamin D plus DHA (Treatment arm) or placebo (Placebo arm). A statistician, who
was blinded to participants’ clinical data and did not participate in patients’ clinical care, gener-
ated the allocation sequence and assigned participants to their group. Only the statistician had
access to the treatment codes. The capsules were taken every day for 24 weeks. Additionally, all
patients were included in a lifestyle intervention program consisting of a hypocaloric diet (25–
30 Kcal/kg/day) and regular physical exercise (twice weekly 1-hour physical activity). Partici-
pants and investigators were blinded to the treatment for the duration of the study. Capsules
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were dispensed at the baseline visit, and after three months. The compliance with treatment
was monitored at each visit by counting the returned capsules. Moreover, at each visit, adverse
effects were recorded by the Principal Investigator. Anthropometric measurements and labora-
tory data were collected at each visit (at baseline, 6 and 12 months). Liver biopsy was performed
at baseline and after 12 months, only in the treatment arm. For ethical reasons and according to
the Position Paper of the Hepatology Committee of ESPGHAN (European Society of Pediatric
Gastroenterology, Hepatology and Nutrition) at the end of study, it was decided to repeat liver
biopsy only in treated patients [24] and patients in the placebo group did not undergo an end of
study biopsy.
We defined changes in NAS as the primary outcome of the present proof of concept trial
because several studies have showed liver histology as the most appropriate endpoint to define
efficacy in clinical trials in NAFLD [25]. The secondary outcomes were the improvement of
metabolic parameters, such as gluco-insulinemic profile and serum lipid concentrations.
Anthropometrical and biochemical measurements
Anthropometric measurements and laboratory tests, including liver enzymes, gluco-insuline-
mic profile and lipids were performed at baseline and repeated at 6 and 12 months.
The body weight and height were measured with the patients wearing underwear. Body
mass index (BMI = kg/m2) and standard deviation score (Z score) were calculated [26].
Serum glucose, lipid profile [triglycerides, cholesterol-total, high-density lipoprotein (HDL)
cholesterol and low-density lipoprotein (LDL)], liver function tests (aspartate- (AST) and ala-
nine- (ALT) aminotransferases, gamma-glutamyl-transpeptidase (GGT), albumin and Inter-
national Normalized Ratio (INR)), fasting plasma glucose and insulin were measured in all
patients after an overnight 12-h fasting. In all patients, Oral Glucose Tolerance Tests (OGTT)
were performed [27]. Insulin-resistance (IR) was assessed by the homeostatic model assess-
ment (HOMA) [HOMA-IR = (insulin0 (μIU/ml) x glucose0 (mmol/l))/22.5)]. A cut-off value
of> 2.5 was considered as an index of insulin resistance [28].
In all patients, serum 25-hydroxyvitamin D [25(OH)D, vitamin D] concentration was mea-
sured by radioimmunoassay (IDS Immunodiagnostics, IDS Limited, Tyne and Wear, UK).
Subjects were categorized as having either low vitamin D levels (<20 ng/mL), or normal vita-
min D levels (20 ng/mL) [29].
Determination of total monthly hours of sunlight
The mean hours of sunshine was determined using the “Italian atlas of solar radiation” from
the ENEA center (http://www.solaritaly.enea.it). The formula for estimating mean hours of
sunlight was: % Sunshine x [(Clear days x 0.85) + (Partly Cloudy days x 0.45) + (Cloudy day x
0.10) x 24]
Sunshine % = the percentage of the daylight hours for Rome during that month;
Clear days = defined as 70%-100% of sunshine; was used for the mean value of85% or 0.85 in
the formula;
Cloudy days = defined as 30%-60% of sunshine; was used for the mean value of 45% or 0.45 in
the formula;
Cloudy Days = defined as 0–20% of sunshine; was used for the mean value of 10% or 0.10 in
the formula [30].
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Liver biopsy
Echo-guided liver biopsy was performed using an automatic core biopsy device (Biopince,
Amedic, Sweden) with an 18-G needle, under general anesthesia [31]. A single experienced
pathologist evaluated liver specimens. The histological features of steatosis (0–3), lobular
inflammation (0–3), and hepatocyte ballooning (0–2) were combined in the NAFLD activity
score (NAS), ranging from 0 to 8 using the criteria of NAFLD Clinical Research Network [32].
Assessment of fibrillar collagen deposition in liver biopsies
The assessment of fibrillar collagen deposition within the liver biopsy was evaluated in Sirius
Red (SR) stains, as previously [33,34]. Briefly, SR stained slides were scanned by a digital scan-
ner (Aperio Scanscope CS System, Aperio Technologies, Inc, Oxford, UK) and processed by
ImageScope. An image analysis algorithm has been used to quantify the proportion of SR-
stained area. The algorithm was applied on the entire section (Part A and B of S1 Fig). The
extent of collagen deposition was expressed as the proportion (%) of SR-stained area with
respect to the total biopsy area, providing a quantitative value on a continuous scale. Only
biopsies containing at least 5 portal tracts were considered.
In order to establish reference values for fibrillar collagen in normal liver samples, speci-
mens from 6 lean, non-diabetic children (boys, 4; girls, 2; median age: 13 years, range, 12–16
years) without liver disease were used as controls, as previously [35]. These fragments were
obtained from patients who underwent laparotomy or laparoscopic procedures (for cholecys-
tectomy), from liver donors (orthotopic liver transplantation) or incidental “normal” liver
biopsies (children exhibiting persistent/intermittent elevations of liver enzymes for >6
months). Informed consent in writing was obtained from next of kin, caretakers, or guardians
on behalf of the children enrolled in this study [35,36].
Immunohistochemistry for α smooth muscle actin and evaluation of
hepatic stellate cell/myofibroblast pool
Sections were incubated overnight at 4˚C with primary antibodies against α smooth muscle actin
(αSMA: Dako, mouse monoclonal, code: M0851, dilution: 1:50). Samples were then incubated
for 20 minutes at room temperature with secondary biotinylated antibody and, successively, with
streptavidin-Horse radish peroxidase (LSAB+, Dako, code K0690). Diaminobenzidine (Dako,
code K3468) was used as the substrate and the sections were counterstained with hematoxylin.
For all immunoreactions, negative controls (the primary antibody was replaced with pre-immune
serum) were also included.
Sections were examined with a Leica Microsystems DM 4500 B Microscopy (Weltzlar, Ger-
many) equipped with a Jenoptik Prog Res C10 Plus Videocam (Jena, Germany). Observations
were processed with an Image Analysis System (IAS, Delta Sistemi, Rome, Italy) and were
independently performed by 2 researches in a blinded fashion. Only biopsies containing at
least 5 portal tracts were considered.
The activation of Hepatic Stellate Cell (HSC)/Myofibroblast (MF) pool was evaluated by
counting the number of αSMA-positive cells per high power field (HPF: at 40x). Perisinusoidal
HSCs and portal/septal MFs were separately evaluated [36,37]; αSMA-positive HSCs were rec-
ognized in accordance with their stellate/spindle shape and their perisinusoidal location within
the parenchymal lobule; besides, portal/septal MFs were considered as stellate- or spindle-
shaped (αSMA-positive cells) located at the interface between parenchyma and portal tract or
between parenchyma and septa, and those residing in the portal tracts and the fibrotic septa.
The number of αSMA-positive HSCs and MFs was counted and expressed as number of
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positive cells per HPF. Only the cells which displayed nuclei on the section were considered.
For each slide, at least 15 non-overlapping microscopic HPFs were randomly chosen.
Ethical Approval
The trial was fully approved by the Ethics Committee of the Bambino Gesu` Children’s Hospital
in January 2014; protocol number: 791.13/0PBG, see S1 Protocol), according to the Declara-
tion of Helsinki (as revised in Seoul, Korea, October 2008) and CONSORT guidelines (see S1
Checklist). A written informed consent to the study protocol and to publication of results was
obtained from the parents or legal guardians of the children. This study was registered on
March 24, 2014 in ClinicalTrials.gov (Registration Number: NCT02098317 –see S1 Clinical
Trial).
The authors confirm that all ongoing and related trials for this drug/intervention are
registered.
Statistical analysis
The data were analyzed using a STATISTICA (version 2010, Chicago, IL, USA). Continuous
variables were expressed as mean ± standard deviation (SD). Data distribution was checked
for normality by the Kolmogorov-Smirnov test. Data were analyzed using the intention-to-
treat principle and the values recorded at baseline were compared to values recorded at 6 and
12 months in all patients, regardless of treatment duration. Baseline and follow up characteris-
tics were tested for differences by Student’s t-test (p<0.05). The change of anthropometrical
and laboratory values, between placebo and treatment groups, was evaluated using analysis of
variance (ANOVA) with repeated measures. Difference between proportions were tested
using the Chi-square test. Univariate correlations were investigated with Pearson’s correlation.
Multivariable logistic regression analysis was used to test the independence of associations
between end of study vitamin D concentrations as the key exposure and histological character-




In our study, between March 2014 and April 2015, 66 patients were screened and 43 of these
with biopsy-proven NAFLD were enrolled (Fig 1). The patients were enrolled with similar
proportions recruited during the winter (20/43, 47%) and spring (23/43, 53%) months.
Twenty patients received an oral dose of 500 mg of DHA and 800 IU/day of Vitamin D
(treatment arm) and 23 children received the capsules of placebo for 6 months (placebo arm).
Forty-one patients completed the study, with two patients from the treatment arm being lost
to follow up. There were no significant adverse events. The dropouts from the treatment arm
were not associated with any study adverse events, but were due to the refusal by parents to
consent to the second liver biopsy at 12 months. The two groups had similar baseline charac-
teristics, as shown in Table 1.
Effects on anthropometric, clinical and laboratory parameters
Table 1 shows the anthropometric and laboratory characteristics for each arm of the study. At
12 months, the placebo group showed no significant improvements for any anthropometric
and laboratory parameters. In the treatment arm, at 12 months, there was a decrease in BMI
(28.42 to 24.58 kg/m2, p = 0.04), serum triglyceride concentration (174.5 to 102.15 mg/dl;
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p = 0.001) and in the measure of insulin-resistance were observed (HOMA-IR 4.59 to 3.42;
p = 0.03). Repeated measures ANOVA showed both treatment and placebo decreased BMI
(F(5,18) = 6.55; p = 0.0001), ALT (F(5,18) = 4.34; p = 0.0003), Triglycerides (F(5,19) = 10.1;
p = 0.0001), insulin-‘120 (F(5,19) = 2.97; p = 0.015) and vitamin D (F(5,18) = 16; p<0.0001).
Vitamin D supplementation
At baseline, all patients showed vitamin D deficiency (VDD), with median values of vitamin D
of 16.01±3.98 ng/dL. The values of vitamin D were normalized to the hours of sunlight. In the
placebo arm, the values of vitamin D did not change during the study, with persistent VDD. In
contrast, in the treatment group, a persistent and significant increase of Vitamin D concentra-
tion was observed (baseline = 15.98; 6-months = 29.7 and 12-months = 25.42 ng/dL; p = 0.02).
None of treated patients developed hypercalcemia and/or nephrotoxicity.
Effects on liver histology
Improvement in liver histology was the primary outcome of the trial. Table 2 showed all histo-
logical features and NAS scores assessed at baseline in both groups and after 12 months in the
treatment group. The data were similar between the two groups at baseline for steatosis, bal-
looning, portal and lobular inflammation and fibrosis. Lower levels of 25 (OH) D3 were associ-
ated with greater fibrosis and steatosis. Before randomization, the biopsies were classified, in
Fig 1. The enrollment flow-chart.
doi:10.1371/journal.pone.0168216.g001
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Table 1. Clinical and laboratory variables in placebo and treatment arms at baseline and 12 months.
Arm Baseline 6 months 12 months Difference between groups p placebo p treatment
Sex (M/F) Placebo 10–13 10–13 10–13
Treatment 9–11 9–11 8–10
Age (years) Placebo 13.20 (2.16) 14.8 (3.26) 14.3 (2.16) F(5,18) = 0.45; p = 0.79 0.11
Treatment 12.30 (2.07) 12.75 (2.42) 13.05 (1.77) 0.16
BMI, Kg/mq Placebo 28.39 (5.42) 28.22 (5.33) 28.02 (5.63) F(5,18) = 6.55; p = 0.01˚ 0.33
Treatment 28.42 (4.08) 27.01 (4.77) 24.58 (3.61) 0.002*
z-BMI Placebo 2.34 (0.89) 2.10 (0.75) 2.07 (0.67) F(5,19) = 0.24; p = 0.04˚ 0.26
Treatment 2.16 (0.64) 1.96 (0.35) 1.67 (0.56) 0.05*
WC, cm Placebo 89.95 (9.91) 89.45(8.77) 89.15 (9.74) F(5,19) = 1; p = 0.07 0.85
Treatment 89.47 (9.35) 86.91 (11.61) 85 (7.29) 0.76
AST, UI/L Placebo 33.05 (18.72) 36.7 (28.87) 35.05 (36.98) F(5,18) = -1.45; p = 0.05˚ 0.47
Treatment 28.55 (10.51) 27.64 (15.54) 20 (23.76) 0.21
ALT, UI/L Placebo 51.20 (52.97) 45.11 (11.12) 43.45 (17.10) F (5,18) = 4.34; p = 0.0003˚ 0.76
Treatment 40.25 (24.59) 34.29 (33.08) 24.5 (16.58) 0.013*
GGT, UI/L Placebo 21.88 (13.45) 20.11(13.4) 18.78 (14.33) F(5,18) = 1.8; p = 0.44 0.52
Treatment 20.05 (12.92) 21.29 (12.91) 18.5 (18.12) 0.22
Total Cholesterol, mg/dl Placebo 154.45 (30.85) 153.1 (15.44) 143.35 (18.41) F(5,19) = 0.68; p = 0.64 0.59
Treatment 163 (27.28) 155.64 (23.83) 157 (25.77) 0.23
LDL Cholesterol, mg/dl Placebo 95.36 (32.74) 100.12 (25.6) 95.38 (33.7) F(5,19) = 3.07; p = 0.013˚ 0.88
Treatment 112.05 (24.28) 107.29 (23.07) 105.5 (22.24) 0.08
HDL Cholesterol, mg/dl Placebo 46.55 (8.53) 42.55 (6.24) 47.51(8.55) F(5,19) = 4; p = 0.07˚ 0.87
Treatment 34.5 (8.55) 41.88 (6.82) 43.77 (7.31) 0.008*
Triglycerides, mg/dl Placebo 87.20 (47.40) 88.94 (41.33) 89.44 (44) F(5,19) = 10.1; p<0.00001˚ 0.43
Treatment 174.5 (75.63) 127.35 (64.30) 102.15 (22.24) <0.0001*
Glucose, mg/dl Placebo 82.50 (7.36) 85.7 (4.18) 80.80 (6.27) F(5,18) = 0.89; p = 0.46 0.52
Treatment 84.85 (6.44) 80.5 (13.08) 77.82 (8.91) 0.49
Glucose-120’ Placebo 100.2 (13.12) 101.2 (12.23) 97.10 (10.21) F(5,18) = 0.61; p = 0.69 0.77
Treatment 102.54 (13.31) 101.8 (11.23) 103 (26.69) 0.94
Insulin, mU/L Placebo 22.31 (14.74) 23.44 (16.4) 21.71 (12.23) F(5,19) = 0.31; p = 0.79 0.96
Treatment 25.03 (21.22) 23.13 (13.60) 21.16 (15.46) 0.33
Insulin -120’ Placebo 77.16 (40.99) 86.3 (24.35) 84.63 (31.53) F(5,19) = 2.97; p = 0.015˚ 0.74
Treatment 123.21 (83.72) 126.99 (70.46) 92 .93 (50.1) 0.04*
HOMA-IR Placebo 4.56 (3.13) 4.28 (2.64) 4.33 (2.52) F(5,19) = 1.27; p = 0.29 0.73
Treatment 4.59 (4.26) 4.29 (2.69) 3.42 (2.90) 0.05*
HbA1c, mmol/mol Placebo 35.31(1.21) 35.22 (1.99) 36.42 (2.96) F(5,19) = 1.27;p = 0.73 0.78
Treatment 34.54 (1.34) 35.48 (1.61) 36.09 (1.45) 0.12
Uric Acid, mg/dl Placebo 5.44 (1.67) 6.01 (1.11) 5.62 (2.96) F(5,18) = 2.46;p = 0.09 0.29
Treatment 5.86 (1.25) 6.27 (2.14) 6.10 (1.15) 0.16
Vitamin D, ng/ml Placebo 16.98 (3.47) 17.01 (3.17) 18.36 (3.87) F(5,18) = 16; p = <0.0001˚ 0.86
Treatment 15.98 (5.03) 29.7 (6.21) 25.42 (4.72) 0.001*
BMI = Body mass index, z-BMI: z-score body mass index, WC = waist circumference, ALT = Alanine aminotransferase, AST = aspartate aminotransferase,
GGT = γ-glutamyltransferase,HDL = high-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, HOMA-IR = homeostatic model
assessment of insulin resistance, HbA1c glycosylated haemoglobin. Data are expressed as means ± standard deviation (SD). Standard deviation: average
standard deviation of blood glucose of the patients during the 24-hour monitoring period.
* ANOVA (p<0.05) between baseline and 12 months.
˚ ANOVA with repeated measures.
doi:10.1371/journal.pone.0168216.t001
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accordance with the NASH CRN-criteria, into Not-NASH (N = 6) and definite NASH
(N = 14). After treatment with DHA and Vitamin D, the classification of biopsies indicated a
decrease of definite NASH (N = 3) and an increase of not-NASH diagnosis (N = 17). More-
over, NAS improved (from 5.40 to 1.92; p<0.001), and steatosis (from 2.25 to 1.0; p = 0.002),
ballooning (from 1.6 to 0.46; p = 0.001), lobular inflammation (from 1.5 to 0.88; p = 0.04) and
portal inflammation (from 1.6 to 1.0; p = 0.05)], whilst there was a trend toward a decrease in




Number (%) 23 (100) 20 (100) pa 18 (90%) pb
Steatosis
0 / / / 5 (35.70) /
1 9(39.13) / / 9 (6.30) /
2 8(34.77) 13(65) 0.06 / /
3 6(26.1) 7(35) 0.31 / /
Lobular Inflammation
0 2(8.7) / / 3 (21.43) /
1 13 (56.52) 15 (75) 0.62 11 (78.57) 0.62
2 8 (34.78) 5 (25) 0.44 / /
Portal inflammation
0 2(8.7) / /
1 15 (65.2) 14 (70) 0.91 14 (100) 0.08
2 6 (26.1) 6 (30) 0.87 / /
Ballooning
0 1(4.35) / / 8 (57.15) /
1 14(60.87) 13(65) 0.44 6 (42.85) 0.41
2 8 (34.78) 7 (35) / / /
NAS
1 / / / 5(35.70) /
2 1(4.35) / / 5(35.70) /
3 6(26.12) / / 4(28.60) /
4 4(17.4) 6(30) 0.21 / /
5 8 (34.78) 10 (50) 0.76 / /
6 3(13) 3(15) 0.99 / /
7 1 (4.35) 1 (5) 0.98 / /
Fibrosis
0 / / / / /
1c 18(78.3) 13(65) 0.09 12(66.6) 0.92
2 5(21.7) 6(30) 0.12 6(33.4) 0.99
3 / 1(5) / / /
α-SMA+ cells (Means ± SD)
pericentral HSCs / 8.64±4.92 / 2.72±2.51 < 0.01
portal MFs / 3.94±1.78 / 2.05±1.49 < 0.05
α-SMA = α smooth muscle actin; HSCs = Hepatic Stellate Cells; MFs = Myofibroblasts; SD = Standard Deviation
a: placebo vs. treatment to baseline
b: treatment baseline vs. treatment 12 months
doi:10.1371/journal.pone.0168216.t002
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fibrosis (from 2.0 to 1.5; p = 0.06). Fibrosis severity at baseline was: stage 1c in 13 samples,
stage 2 in 6, stage 3 in 1, and there were no biopsies that were classified as fibrosis stage 4.
After treatment, no statistical significant changes were present in fibrosis stage [stage 1c: 12
patients; stage 2: 6 patients; (stages 3–4: no patients)].
Binary logistic regression analysis showed that change in Vitamin D level with treatment
was independently associated with features of NAFLD as dichotomous outcomes [fibrosis
(OR = 2.96, 95% CI = 1.9–4.69, p-value = 0.003), steatosis (OR = 3.53, 95% CI = 1.33–3.4, p-
value = 0.001) and NAS (OR = 2.75, 95% CI = 1.2–3.32, p-value = 0.005) (Table 3)].
Fibrosis and collagen deposition assessment in liver biopsies
Since the available evidence suggests that vitamin D may have a beneficial effect on fibrogen-
esis and as we observed a trend toward an improvement in fibrosis score with treatment, fur-
ther exploratory analyses were undertaken to examine the effects of treatment on factors
involved in the fibrogenetic process. The fibrillar collagen content was assessed in SR stained
biopsies at baseline; overall, NAFLD biopsies at baseline showed increased but not statistically
significant values of fibrillar collagen content (2.60 ± 1.76), compared with normal controls
(1.44 ± 0.41; p = 0.088). Only eleven out of twenty NAFLD biopsies at baseline showed
increased content of collagen fibers (3.51 ± 1.66) in comparison with normal samples
(p<0.01). Moreover, biopsies with a fibrosis score = 2/3 (N = 7) had higher fibrillar collagen
content (4.17 ± 2.10) in comparison with those obtained from patients with fibrosis score = 1
(1.90 ± 1.11; p< 0.05).
At the baseline, the fibrillar collagen content calculated in SR stained slides was significantly
correlated with fibrosis stage (r = 0.647; p<0.02) and NAS score (r = 0.736; p<0.01).
Patients with an increased fibrosis content at the baseline (N = 11) showed a significant
decrease in fibrillar collagen content at the end of the treatment (1.59 ± 1.37 v. x; paired t-test:
t = 3.86 p = 0.003; Fig 2).
Activation of HSC/MF pool. The activation of HSC/MF pool was evaluated at the base-
line and at the end of the treatment by immunohistochemistry for αSMA.
At the end of the treatment, the number of αSMA+ HSCs/MFs was significantly reduced
(pericentral HSC = 2.72±2.51 and periportal MFs = 2.05±1.49) compared with biopsies at
baseline (paired t-test: t = 4.60 p< 0.01 and t = 3.53, p<0.05, Fig 2).
Discussion
To the best of our knowledge, this is the first RCT evaluating the efficacy of treatment with
DHA plus Vitamin D in NAFLD/NASH patients with vitamin D deficiency, using changes in
Table 3. Binary logistic regression showing the effect of increase in vitamin D levels with treatment on change in liver histology characteristics.
Variables Unadjusted OR (95% CI)a p-value Adjusted OR (95% CI)b p-value
Ballooning 3.7(0.99–4.9) 0.28 2.1(0.78–3.6) 0.13
Fibrosis 5.48(2.01–8.7) 0.001 2.96 (1.9–4.69) 0.003
Steatosis 6.77(2.79–10.4) 0.001 3.53(1.33–3.4) 0.001
Lobular Inflammation 5.44(1–7.99) 0.25 2.5(0.93–3.3) 0.11
Portal Inflammation 4.74(2.44–5.77) 0.05 1.82(1.22–2.33) 0.05
NAS score 4.89(2.11–8.64) 0.006 2.75(1.2–3.32) 0.005
a: unadjusted analysis
b: adjusted for BMI and basal Vitamin D concentration
doi:10.1371/journal.pone.0168216.t003
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liver histology as the primary end-point. In accord with a previous study testing the effect of
DHA treatment in pediatric NAFLD, the results of our study show that the administration of a
mixture of DHA and vitamin D was associated with an improvement in insulin resistance with
a concomitant reduction of serum triglyceride concentration and an improvement in ALT
concentration. In Table 4 we have compared the effect of treatment in the presented trial with
that of our previous DHA trial in pediatric NAFLD [18], in order to test whether there were
more marked effects in the DHA plus vitamin D intervention. These data show there were no
significant differences between the trials for differences in triglyceride concentrations,
HOMA-IR or ALT levels; thus, these comparative data suggest that treatment with DHA plus
vitamin D is not better than DHA treatment alone in producing an improvement in these
parameters (that are often abnormal in patients with NAFLD). Therefore, the data suggest that
Fig 2. Assessment of fibrillar collagen content and activation of hepatic stellate cells (HSCs) in liver biopsies. (A) The fibrillar collagen
content was assessed in Sirius Red (SR) stained biopsies. Patients with an increased collagen content at the baseline (N = 11) showed a
significant decrease in fibrillar collagen content at the end of the treatment. (B) The activation of HSCs and portal Myofibroblasts (MF) was
evaluated by immunohistochemistry for α Smooth Muscle Actin (αSMA). At the end of the treatment, the number of αSMA+ HSCs and portal MFs
was significantly reduced in comparison with biopsies at the baseline.
doi:10.1371/journal.pone.0168216.g002
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the amelioration of the metabolic profile observed in our patients in the current trial is proba-
bly related to the DHA treatment alone, rather than to the vitamin D treatment.
The presented data are also in accord with other studies in which supplementation of vita-
min D in obese children did not affect the lipid profile and markers of insulin resistance and
inflammation [38,39]. In contrast to our previous trial, in the presented study we observed a
reduction of BMI in the treatment arm at the end of the trial (12 months).
The greater weight decrease in the treatment arm may be due better adherence in this
group of children to the therapeutic lifestyle advice that was given to all participants. It is well
accepted that weight loss can improve the early features of NAFLD, but it is important to note
that the benefit of the intervention was independent of weight loss in the treatment arm of the
study.
Regarding our primary outcome, NAS improved in all treated patients, with a significant
reduction of steatosis, ballooning, portal and lobular inflammation. In fact, 14/20 patients with
NASH at baseline improved with treatment. This improvement in NAS was similar to that
observed in our previous trial testing the effects of DHA treatment alone in pediatric NASH
(p<0.05, Table 5) [35].
Moreover, bearing in mind the potential for benefit of vitamin D treatment on fibrosis in
NAFLD and the known prognostic implication of liver fibrosis for serious chronic liver dis-
ease-related outcomes, we evaluated the effects of treatment on changes in fibrosis score in the
treatment arm. In recent years, the role of vitamin D in metabolic syndrome and cardiovascu-
lar risk has attracted considerable attention and several reports suggest a crucial role for vita-
min D in NAFLD development and progression. A recent systematic review demonstrated
that patients with NAFLD were 1.26-times more likely to be vitamin D deficient compared
with controls [15]. Moreover, both in adults and in children, studies show that low levels of
vitamin D are associated with NAFLD, independently of known metabolic risk factors [18,40].
Deficiency of vitamin D may play a role in the development of fibrosis in NAFLD. For
example, Zhu et al reported that long-term vitamin D deficiency can provoke chronic liver
inflammation, inducing apoptosis and activation of hepatic stellate cells (HSC) to initiate liver
Table 4. The percentage change in anthropometric and biochemical tests with treatment for the DHA
+vitamin D intervention group in the presented study compared with the percentage change in the
same parameters with DHA treatment alone [22] from a previous study.
% change with treatment
DHA/vitD DHA P
BMI, Kg/m2 -13.51 ±2.1 -4.13±3.1 0.02
WC, cms -4.99 ±1.1 -5.17±2.4 0.67
z-BMI (SDS) -12.54±0.1 -3.98±0.4 0.01
AST, IU/L -29.94±2.1 -35.41±2.5 0.12
ALT, IU/L -39.13±3.9 -41.56±4.3 0.24
GGT, IU/L -1.99±1.4 +1.19±1.6 0.09
Total Chol, mg/dL -3.60±1.5 -18.87±2.4 0.05
LDL Cholesterol, mg/dL -5.85±2.4 -19.63±3.3 0.01
HDL cholesterol, mg/dL +21.19±1.8 -19.64±3.7 0.02
Triglycerides, mg/dL -41.46±1.7 -12.98±2.4 0.01
Glucose-0’, mg/dL -3.19±2.5 -7.44±3.1 0.23
Glucose-120’, mg/dl -10.19±5.4 -14.42±2.9 0.44
Insulin-0’, mU/L -24.57±6.2 -32.52±7.1 0.13
Insulin -120’, mU/L -15.47±4.3 -11.65±5.4 0.75
HOMA-IR -22.29±1.4 -39.55±1.6 0.09
doi:10.1371/journal.pone.0168216.t004
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fibrosis [41]. There is also evidence indicating that vitamin D is able to modulate HSC activa-
tion in vitro and to reduce liver fibrosis in experimental models of liver injuries [21,33].
Despite a clear and marked improvement in the NAS, there was only a non significant trend
toward an improvement in fibrosis score. In keeping with this trend toward an improvement
in fibrosis score, our results indicate that vitamin D administration reduces the activation of
HSC/MF pool and, in patients with increased fibrillar collagen content, we observed signs of
total collagen content reduction at the end of treatment.
Results from experimental cirrhosis in rats indicate that vitamin D treatment is able to pre-
vent liver fibrosis but does not ameliorate established cirrhosis [42]. In keeping with these
data, no patients included in our trial presented with bridging fibrosis or established cirrhosis
at baseline. Consequently, our results are relevant only to the early phases of fibrogenesis and
the data suggest there is a benefit of reduced activation of fibrogenetic cells (HSC/MF pool)
after the treatment with vitamin D.
The presented study has some limitations. The first is the lack of an end of study liver
biopsy in the placebo group. For ethical reasons, bearing in mind that our patients are chil-
dren, the liver biopsy was not repeated at 12 months in this group. Additionally, it was not pos-
sible to test separate effects of DHA and vitamin D in this trial by using a 2x2 factorial study
design and as this was a proof of concept study that lacked an end of study biopsy in the pla-
cebo group, we did not attempt a sample size calculation. A second limitation is that none of
our patients showed bridging fibrosis or cirrhosis at baseline and, thus, the observed results
are limited to the early stages of fibrogenesis. Therefore, it is remains uncertain whether this
treatment is effective in modifying the fibrogenetic pattern in more advanced stages of liver
fibrosis (F3-F4). Another limitation could be the dosage of vitamin D used in our study (800
IU daily), which although twice the average daily requirement of vitamin D, is lower than the
dosage prescribed in previous clinical trials in adults with NASH. Actually, data regarding the
safety of vitamin D supplementation in pediatric NAFLD is lacking. Consequently, we consid-
ered it necessary to use this dosage of vitamin D for only six months, in order to avoid possible
adverse effects. For ethical reasons, we repeated the liver biopsy in our patients after one year
(and not at 6 months) after randomization.
In conclusion, the results of our proof of concept study have shown beneficial effects of
DHA plus vitamin D treatment on insulin-resistance, ALT triglyceride concentration and
NAS score in VDD patients with biopsy-proven NAFLD. The combination of 500 mg o.d. of
DHA and 800 IU o.d. vitamin D was safe over 6 months of intervention. The supplementation
of a mixture of DHA and vitamin D in VDD obese children and adolescents with NAFLD may
induce a remodeling of the fibrogenetic pattern with a reduction of the activation of the HSC/
MF pool and of collagen content. We suggest that further longer-term studies are now
Table 5. Differences in histological characteristics with treatment with the DHA + vitamin D intervention in the presented study and the differences
in histological characteristics with DHA treatment alone for comparison from a previous study [22].
Interventon DHA + Vitamin D Intervention DHA alone
Baseline End of study p-value Baseline End of study p-value
Steatosis 2.25±0.42 1±0.1 0.002 1.70±1.08 0.50±0.61 <0.001
Balloning 1.6±0.47 0.46±0.49 <0.001 0.85±0.67 0.25±0.44 <0.001
Lobular Infl 1.5±0.44 0.88±0.33 0.04 1.15±0.59 0.85±0.37 <0.05
Portal Infl 1.6±0.45 1±0.11 0.05 - - -
Fibrosis 2±0.26 1.5±0.5 0.06 1.60±0.60 1.45±0.76 0.48
NAS 5.4±0.81 1.92±0.92 <0.001 3.70±1.78 1.60±1.05 <0.01
doi:10.1371/journal.pone.0168216.t005
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warranted in both adults and children, including a greater number of patients with more
advanced stage of fibrosis, in order to confirm our preliminary results.
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